We propose that baseline peripheral blood CD4+CD45RA− T-cell counts can be used as a biomarker for predicting the efficacy of ICIs, especially for the second line and beyond patients, whose tumor tissue acquisition is difficult. The gene discussed is CD4; the disease is neoplasm.